Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$134.97 USD
+1.90 (1.43%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $135.07 +0.10 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 141 - 160 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Making It Official - FDA Places Clinical Hold On RESTORE-1
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 12/11/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
COVID, Script Trends Warrant Revisiting Our Ingrezza Assumptions
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 11/13/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Miss But Focused On The Longer-Term Outlook; COVID Can''t Last Forever
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Continued Focus on Long-Term Potential of Ingrezza and a Deep Dive on NBI-827104; Reit Buy and $140 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker -- Week Ending
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 10/23/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 10/16/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 9/18/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Sustained Motor Function Improvement in Phase 1 Gene Therapy Trial Supports NBIb-1817 Progress in PD; Reit $140 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Worth The Wait; Encouraging VY-AADC 2-/3-Year Update Puts Durability On Display
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L